TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00089479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 825mg/m2 po bid on days 1-14 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75mg/m2 iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: 100mg/m2 iv on day 1 of each 3 week cycle
Study: NCT02783144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block and Dexamethasone
Description: After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block and saline
Description: After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block and Dexamethasone i.v.
Description: After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
Study: NCT01119157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
Study: NCT00074802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will consist of 16 weekly treatment sessions.
Study: NCT04724733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Sense
Description: Smoke Sense is a smartphone application (app). Smoke Sense participants will be asked to establish a profile which includes demographics, baseline health information and current beliefs about smoke and air pollution. In the Symptoms \& Smoke Observations tab, participants are asked to report their weekly observations of smoke, health symptoms, and exposure reduction behaviors. In the Fire \& Smoke Near Me tab, participants review the most recent AQ data measured at an AQ monitoring sites. Participants are asked to complete the AQ 101 module which test knowledge of AQ facts and provides correct answers. Badges are awarded for accomplishments within the app to promote certain desired behaviors: completing a user profile, launching the app weekly to check local AQ, reporting smoke and symptom observations, expanding AQ knowledge with AQ lessons, and exploring the map. Finally, participants can engage with other users by viewing cumulative statistics of symptoms and smoke observations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Sense Plus
Description: Participants randomized to the Smoke Sense Plus intervention will be asked to do everything that the Smoke Sense intervention group does on a weekly basis, as well as: 1) Receive weekly push notifications that remind them to, for example, review their asthma action plan, refill any expired medications, take their daily controller medication, identify a clean air space in their home and community, 2) Monitor their lung function weekly via mobile spirometry, and 3) Subscribe to a social network to share strategies to minimize exposure.
Study: NCT01055418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
Study: NCT03593811

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetogastrogram (MGG)
Description: MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetogastrogram (MGG)
Description: MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetogastrogram (MGG)
Description: MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
Study: NCT01055418

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
Study: NCT03593811

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram (EKG)
Description: Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram (EKG)
Description: Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram (EKG)
Description: Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
Study: NCT02645279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral 30% glucose
Description: 30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV midazolam
Description: IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
Study: NCT04152642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Dry Mouth Rinse
Description: relieves dry mouth symptoms by physically coating oral mucosal surfaces.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water control
Description: negative control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Dry Mouth Rinse
Description: relieves dry mouth symptoms by physically coating oral mucosal surfaces.
Study: NCT01577199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Clomiphene
Description: Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose gonadotropins
Description: Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
Study: NCT03181477

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiotherapy
Description: Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
Study: NCT01030380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slendertone Face
Description: Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
Study: NCT04522934

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical Education
Description: Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
Study: NCT03201887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-optimal effort
Description: Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-optimal effort
Description: Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: optimal effort
Description: Participants will be asked to perform tasks to the best of their abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: optimal effort
Description: Participants will be asked to perform tasks to the best of their abilities.
Study: NCT01025687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with noncalorie sweetener

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with glucose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program showed while feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV program showed while feeding
Study: NCT00570440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptives--ethinyl estradiol, levonorgestrel
Description: 3 visits - screening/enrollment, 6-months and 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptives--ethinyl estradiol, levonorgestrel
Description: 3 visits - screening/enrollment, 6-months and 12 months
Study: NCT01313481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group exercise
Description: Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
Study: NCT03316677

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraoperative testing of colorectal anastomoses
Description: 1. Insert a Foley catheter through the anus into the rectum.~2. Insufflate the Foley balloon with 5 cc of air.~3. Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~4. Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~5. Remove the saline from the pelvic space.~6. Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~7. Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stapled colorectal anastomoses
Description: After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
Study: NCT03593811

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram (EKG)
Description: Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram (EKG)
Description: Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine Oral Tablet
Description: Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
Study: NCT00049218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell-adenovirus p53 vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT03526315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP paste
Description: Children will brush their teeth with CPP-ACP paste twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Children will brush their teeth with fluoridated toothpaste twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Both (Fluoride and CPP-ACP)
Description: Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
Study: NCT03109756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101
Description: Single-dose 5 mg OV101
Study: NCT02776501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987521)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: Y49-103)
Study: NCT00500838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic Impedance
Description: Impedance measures will be automatically collected via the device
Study: NCT04635761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01484145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine HCl
Description: 4% w/w terbinafine HCL gel, single dose,
Study: NCT00564226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR240600C
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR240600C
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR240600C
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT00952549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Yoga Toning Program
Description: Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
Study: NCT03501914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome \& introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
Study: NCT00001586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituxan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Fludara
Study: NCT01484145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine HCl
Description: 4% w/w terbinafine HCL gel, single dose,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine HCl
Description: 4% w/w terbinafine HCL gel, single dose,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine HCl
Description: 4% w/w terbinafine HCL gel, single dose,
Study: NCT02538367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 IR 0.05mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 IR 0.1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 IR 0.3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 IR 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 IR 1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 IR 2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 IR 3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 DR1 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 DR1 1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 DR1 2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 DR1 4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 DR2 8mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride 2mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00430963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin) (20 Units)
Study: NCT03609905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose-cord mesenchymal stromal cells (A-MSCs)
Description: A-MSCs 5 x 10\~7 diluted on 100 mL of normal saline

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional drugs
Description: 5-amino-salicylic acid or glucocorticoid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional drugs
Description: 5-amino-salicylic acid or glucocorticoid
Study: NCT00001586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leukemic or stroma cells
Description: Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
Study: NCT01547949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cultivar Montmorency cherry juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo cherry fruit drink
Study: NCT01965392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education intervention
Description: 'Health education intervention'
Study: NCT00943462

Intervention type: RADIATION
Intervention: External-beam radiation therapy
Description: 60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions

Intervention type: DRUG
Intervention: Temozolomide
Description: The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
Study: NCT00093600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Study: NCT00343239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days
Study: NCT01529918

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: CANRISK (Canadian Diabetes Association Assessment)
Description: Self-risk assessment questionnaire for diabetes
Study: NCT00430963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03402100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eye drops
Description: children who received daily eye drops for myopia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eye drops
Description: children who received daily eye drops for myopia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eye drops
Description: children who received daily eye drops for myopia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eye drops
Description: children who received daily eye drops for myopia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eye drops
Description: children who received daily eye drops for myopia
Study: NCT04535089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: receive IV bolus dose of 0.5 ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5 ug/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Iv
Description: IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h